The applications of miniprobe endoscopic ultrasonography in the diagnosis and treatment of colorectal submucosal lesions.

Objectives: To evaluate the efficacy of miniprobe endoscopic ultrasonography for the diagnosis and adjuvant treatment of patients with colorectal submucosal lesions. METHODS: The retrospective study was conducted at the Beijing Chao-Yang Hospital, Capital Medical University, China, and comprised data from January 1, 2016, to July 31, 2021, related to patients of either gender with colorectal submucosal lesions who underwent miniprobe endoscopic ultrasonography. The findings were compared with biopsy specimens and clinical diagnoses. Diagnostic features of miniprobe endoscopic ultrasonography were assessed along with its accuracy. Data was analysed using R 4.1.2. RESULTS: Of the 237 patients, 121(51.1%) were female and 116(48.9%) were male. The overall mean age was 55.6±12.9 years. Miniprobe endoscopic ultrasonography successfully imaged all 237(100%) colorectal submucosal lesions, and 188(79.3%) had consistent results compared to histopathological findings. The majority of lesions were <10mm 102(43.4%) or 10-19mm 84(35.7%) in size. Those detected with high echogenicity were 126(53.2%) and those with low/low-medium echogenicity were 83(35.0%). Tumour size 10-19mm and uneven echo quality significantly increased the accuracy of miniprobe endoscopic ultrasonography (p<0.05). CONCLUSIONS: Miniprobe endoscopic ultrasonography was able to provide precise information about the size, layer of origin, echogenicity and border of colorectal submucosal lesions, and had a high accuracy in the differential diagnosis of such lesions.

Sobrevida en adultos mayores con cáncer colorrectal: una revisión bibliográfica / Survival in older adults with colorectal cancer: a literature review

RESUMEN Fundamento: el cáncer colorrectal es la neoplasia maligna más frecuente que se puede presentar en el sistema digestivo. Se ha observado un incremento gradual en América Latina, Cuba presenta indicadores de salud similares a las naciones desarrolladas, el cáncer colorrectal constituye la tercera causa de muerte entre las enfermedades malignas. Objetivo: proporcionar una recopilación teórica y actualizada de investigaciones relacionadas con la sobrevida en adultos mayores con cáncer colorrectal. Métodos: se realizó una revisión bibliográfica con el método de análisis bibliográfico sin restricciones de idioma, se consultaron las bases de datos Lilacs, Medline, PubMed y SciELO. Se utilizaron como palabras claves: sobrevida, cáncer colorrectal, adulto mayor. Resultados: el cáncer colorrectal puede cursar asintomático, la sintomatología y los signos también dependerán de la localización del tumor. En su mayoría, se detecta en la etapa sintomática, un 50 % de estos pacientes de diagnóstico tardío se encuentran en un estadio avanzado del tumor. La sobrevida de los adultos mayores con cáncer colorrectal depende también de su forma de presentación y calidad de vida. Conclusiones: la sobrevida en adultos mayores con cáncer colorrectal está influenciada por la edad del paciente, estadio en el momento del diagnóstico, forma de presentación de la enfermedad nosológica, abordaje quirúrgico, estilo y calidad de vida antes y después de ser diagnosticado.

ABSTRACT Background: colorectal cancer is the most common malignant neoplasia that can occur in the digestive system. There has been a gradual increase in Latin America, Cuba presents health indicators similar to developed nations, and colorectal cancer is the third cause of death. Objective: to provide a theoretical and updated collection of research related to survival in older adults with colorectal cancer. Methods: a bibliographic review was carried out with the bibliographic analysis method without language restrictions, the Lilacs, Medline, PubMed and SciELO databases were consulted. They were used as keywords: survival, colorectal cancer, elderly. Results: colorectal cancer can be asymptomatic, the symptoms and signs will also depend on the location of the tumor. Colorectal cancer, for the most part, is detected in the symptomatic stage, 50% of these late diagnosis patients are in an advanced stage of the tumor. The survival of older adults with colorectal cancer also depends on their presentation and quality of life. Conclusions: survival in older adults with colorectal cancer is influenced by the patient's age, stage at the time of diagnosis, presentation of the nosological entity, surgical approach, style and quality of life before and after being diagnosed.

Acurácia diagnóstica de teste quantitativo imunoquímico fecal com uma amostra ou com duas amostras para detectar neoplasia intestinal / Diagnostic accuracy of one sample or two samples quantitative fecal immunochemical tests for intestinal neoplasia detection

ABSTRACT BACKGROUND: Rectal bleeding is the most important symptom of intestinal neoplasia; thus, tests of occult blood detection in stools are widely used for pre neoplastic lesions and colorectal cancer (CRC) screening. OBJECTIVE: Evaluate the accuracy of OC-Sensor quantitative test (Eiken Chemical, Tokyo, Japan) at cut-off 10 µg Hb/g feces (50 ng/mL) in a cohort of subjects that had to undergo diagnostic colonoscopy, and if more than one sample collected in consecutive days would improve the diagnostic accuracy of the test. METHODS: Patients (mean age 56.3±9.7 years) that underwent colonoscopy prospectively randomly received one (1-sample FIT, FIT 1) or two (2-sample FIT, FIT 2) collection tubes. They collected the stool sample before starting colonoscopy preparation. Samples were analyzed by the OC-Auto Micro 80 (Eiken Chemical, Tokyo, Japan). The performance of FIT 1 and FIT 2 were compared to the colonoscopy findings. RESULTS: Among 289 patients, CRC was diagnosed in 14 (4.8%), advanced adenoma in 37 (12.8%), early adenoma in 71 (24.6%) and no abnormalities in 141 (48.8%). For FIT 1, the sensitivity for CRC was 83.3% (95%CI 36.5-99.1%), for advanced adenoma was 24% (95%CI 10.1-45.5%), with specificity of 86.9% (95%CI 77.3-92.9%). For FIT 2, the sensitivity for CRC was 75% (95%CI 35.6-95.5%), for advanced adenoma was 50% (95%CI 22.3-77.7%), with specificity of 92.9% (95%CI 82.2-97.7%). The positive likelihood ratios were 1.8 (95%CI 0.7-4.4 for FIT 1) and 7.1 (95%CI 2.4-21.4 for FIT 2) for advanced adenoma, and 6.4 (95%CI 3.3-12.3, for FIT 1) and 10.7 (95%CI 3.8-29.8, for FIT 2) for CRC. The negative likelihood ratio were 0.9 (95%CI 0.7-1, for FIT 1) and 0.5 (95%CI 0.3-0.9, for FIT 2) for advanced adenoma, and 0.2 (0.03-1.1, for FIT 1) and 0.3 (0.08-0.9, for FIT 2) for CRC. The differences between FIT 1 and FIT 2 performances were not significant. However, the comparison of the levels of hemoglobin in feces of patients of FIT 1 and FIT 2 showed that the differences between no polyp group and advanced adenoma and CRC were significant. CONCLUSION: The accuracy of OCR Sensor with 10 µg Hb/g feces cut-off was comparable to other reports and two-sample collection improved the detection rate of advanced adenoma, a pre neoplastic condition to prevent CRC incidence.

RESUMO CONTEXTO: Sangramento retal é o sintoma mais importante de neoplasia intestinal; portanto, testes para detecção de sangue oculto nas fezes são amplamente usados para rastreamento de lesões pré-neoplásicas e de câncer colorretal (CCR). OBJETIVO: Avaliar a acurácia do teste quantitativo OC-Sensor (Eiken Chemical, Tokyo, Japan) com o valor de corte de 10 µg Hb/g fezes (50 ng/mL) numa coorte de indivíduos que se submeteram à colonoscopia diagnóstica, e se mais de uma amostra coletada em dias consecutivos melhoraria a acurácia diagnóstica do teste. MÉTODOS: Pacientes (idade média 56,3±9,7 anos) que se submeteram à colonoscopia prospectivamente, randomicamente, receberam tubos de coleta: um (1-amostra FIT, FIT 1), ou dois (2-amostra FIT, FIT 2). Eles coletaram as amostras de fezes antes de iniciar o preparo da colonoscopia. As amostras foram analisadas pelo OC-Auto Micro 80 (Eiken Chemical, Tokyo, Japan). As performances do FIT 1 e do FIT 2 foram comparadas com os achados da colonoscopia. RESULTADOS: Entre 289 pacientes, CCR foi diagnosticado em 14 (4,8%), adenoma avançado em 37 (12,8%), adenoma precoce em 71 (24,6%) e sem anormalidades em 141 (48,8%). Para FIT 1, a sensibilidade para CCR foi 83,3% (95%IC 36,5-99,1%), para adenoma avançado foi 24% (95%IC 10,1-45,5%), com especificidade de 86,9% (95%IC 77,3-92,9%). Para FIT 2, a sensibilidade para CCR foi 75% (95%IC 35,6-95,5%), para adenoma avançado foi 50% (95%IC 22,3-77,7%), com especificidade de 92,9% (95%IC 82,2-97,7%). A razão de verossimilhança positiva foi 1,8 (95%IC 0,7-4,4 para FIT 1) e 7,1 (95%IC 2,4-21,4 para FIT 2) para adenoma avançado, e 6,4 (95%IC 3,3-12,3, para FIT 1) e 10,7 (95%IC 3,8-29,8, para FIT 2) para CCR. A razão de verossimilhança negativa foi 0,9 (95%IC 0,7-1, para FIT 1) e 0,5 (95%IC 0,3-0,9, para FIT 2) para adenoma avançado, e 0,2 (0,03-1,1, para FIT 1) e 0,3 (0,08-0,9, para FIT 2) para CCR. As diferenças de performance entre FIT 1 e FIT 2 não foram significantes. Entretanto, a comparação dos níveis de hemoglobina nas fezes dos pacientes de FIT 1 e FIT 2 mostraram que as diferenças entre sem pólipo e adenoma avançado e CCR foram significantes. CONCLUSÃO: A acurácia do OCR Sensor com valor de corte de 10 µg Hb/g de fezes foi comparável a outras publicações e a coleta de duas amostras melhorou a taxa de detecção de adenoma avançado, lesão pré-neoplásica, para prevenir CCR.

The Influence of the Genetic and Immunologic Context in the Development of Colorectal Adenoma: A Case Series Report.

INTRODUCTION: Overcoming immunosurveillance is a major step in the progression of many types of tumors. Several immune escape strategies have been identified, including immunoediting and the establishment of an immune suppressive microenvironment. The aim of the present study was to determine whether the hereditary or sporadic context has any influence in the relationship between immune surveillance and tumor development, using sporadic and familial adenomatous polyposis related colorectal adenomas as a model. MATERIAL AND METHODS: The immune tumor-infiltrating cells of a total of 58 low-grade and 18 high-grade colorectal adenomas were examined and compared, using immunostaining for CD3, CD4, CD8, CD57, CD68 and FoxP3. RESULTS: FoxP3 and CD68 counts were significantly higher in sporadic low-grade dysplasia (p = 0.0003 and p = 0.0103, respectively),and FoxP3 and CD4 counts were found to be significantly higher in high-grade sporadic dysplasia (p = 0.0008 and p = 0.0018, respectively)when compared with corresponding lesions in patients with familial adenomatous polyposis. DISCUSSION: This study suggests that the immune microenvironment of sporadic and hereditary lesions is different. Sporadic lesions contain a higher number of immune suppressive Treg cells, which suggests a stronger immune selective pressure. In contrast, hereditarylesions seem to benefit from a more tolerant immune microenvironment, allowing for the development of lesions with lower immune cell infiltration. CONCLUSION: This study shows that sporadic lesions harbor higher tumor-infiltrating immune cell counts, which might reflect a higher immune tolerance towards hereditary lesions.

Introdução: A capacidade de contornar a imunovigilância é fundamental na progressão de muitos tumores. Já foram identificadas várias estratégias de escape imunológico, incluindo immunoediting e o estabelecimento de um microambiente imunológico supressivo. O objetivo do presente estudo passa por determinar se o contexto hereditário ou esporádico influencia a relação entre a imunovigilância e o desenvolvimento do tumor, usando adenomas coloretais esporádicos e hereditários, no contexto de polipose adenomatosa familiar, como modelos. Material e Métodos: Os infiltrados imunológicos tumorais de um total de 58 adenomas coloretais de baixo grau e de 18 de alto grau foram avaliados e comparados, usando imunohistoquímica com marcação para CD3, CD4, CD8, CD57, CD68 e FoxP3. Resultados: As contagens celulares com imunorreatividade para FoxP3 e CD68 foram significativamente mais elevadas na displasia esporádica de baixo grau (p = 0,0003 e p = 0,0103, respetivamente), enquanto que as contagens para FoxP3 e CD4 foram significativamente mais elevadas na displasia esporádica de alto grau (p = 0,0008 e p = 0,0018, respetivamente) quando comparadas com lesões correspondentes em doentes com polipose adenomatosa familiar. Discussão: O presente estudo sugere que o microambiente imunológico de lesões esporádicas e hereditárias é diferente. As lesões esporádicas contam com um número superior de células T reguladoras, supressoras da função imunológica, sugerindo-se uma pressão imune seletiva mais forte. Por seu turno, as lesões hereditárias parecem beneficiar de um microambiente imunológico mais tolerante, permitindo o desenvolvimento de lesões com menor infiltrado celular imune. Conclusão: Este estudo demonstra que as lesões esporádicas contam com contagens de infiltrados imunológicos tumorais superiores, o que poderá refletir uma maior tolerância imunológica face a lesões hereditárias.

Multitarget Stool DNA for Average Risk Colorectal Cancer Screening: Major Achievements and Future Directions.

After 2 screen-setting studies showing high sensitivity for colorectal cancer and advanced precancerous lesions, multitarget stool DNA testing was endorsed by the US Preventative Services Task Force as a first-line colorectal cancer screening test. Uptake has increased exponentially since approval by the US Food and Drug Administration and Centers for Medicare and Medicaid Services. Adherence to testing is approximately 70%. Patients with positive results have high diagnostic colonoscopy completion rates in single-center studies. The positive predictive value for colorectal neoplasia in postapproval studies is high. Next-generation test prototypes show promise to extend specificity gains while maintaining high sensitivity.

Multi-Target Stool DNA Testing for Colorectal Cancer Screening: Emerging Learning on Real-world Performance.

PURPOSE OF REVIEW: Multi-target stool DNA (MT-sDNA) was approved in 2014 for use in screening average-risk patients for colorectal cancer (CRC). Here, we highlight recent literature from post-market studies to provide an update on clinical use and utility not possible from pre-approval studies. RECENT FINDINGS: MT-sDNA has been included in major society guidelines as an option for colorectal cancer screening, and has seen exponentially increasing use in clinical practice. MT-sDNA appears to be attracting new patients to CRC screening, and patient adherence to diagnostic colonoscopy after a positive MT-sDNA test is high. Approximately two-thirds of these patients are found to have colorectal neoplasia (CRN), 80% of whom have at least one right-sided lesion; 1 in 3 will have advanced CRN. High yield of CRN is due not only to post-screening increase in probability but also likely improved endoscopist attention. In those with a negative high-quality colonoscopy after positive MT-sDNA test ("false positive MT-sDNA"), further interventions do not appear to be necessary. SUMMARY: MT-sDNA is a promising tool to improve rates and quality of CRC screening. Further investigation should examine MT-sDNA performance in populations at increased risk for CRC, and as an interval test after colonoscopy to detect potentially missed lesions.

Comportamiento del cáncer colorrectal en el Hospital Provincial Clínico Quirúrgico Docente Amalia Simoni / Behavior of colorrectal cancer Amalia Simoni Clinical Surgical Teaching Hospital

RESUMEN Fundamento: el intestino grueso se extiende desde el ciego hasta el orificio del ano. El colon es el segmento del sistema digestivo que con mayor frecuencia se ve afectado por tumores. Objetivo: describir el comportamiento del cáncer colorrectal. Métodos: se realizó un estudio observacional descriptivo de corte transversal. El universo fue 106 pacientes con diagnóstico de cáncer colorrectal. Se aplicó un muestreo no probabilístico al juicio, el mismo se conformó por 87 pacientes. La información se extrajo de las historias clínicas, registro de procederes e informes de estudio histológico. Resultados: la edad que predominó fue entre 60-69 años, el sexo femenino fue el más frecuente. Dominó el cambio en el hábito intestinal como manifestación clínica. Se acentuaron las localizaciones de rectosigmoide como la más afectada por los tumores. Los adenocarcinomas fueron los tipos anatomopatológicos que se destacaron. Conclusiones: predominaron los pacientes en el grupo de edades entre 60-69 años y del sexo femenino. La localización más frecuente de la tumoración de colon fue en el rectosigmoide. El tipo histológico de la lesión más frecuente fue el adenocarcinoma donde se halló en más de la mitad de los casos.

ABSTRACT Background: the large intestine extends from the cecum to the orifice of the anus. The colon is segment of the digestive system that with greater frequency is affected by tumors. Objective: to determine the behavior of colorectal cancer. Methods: a cross-sectional descriptive observational study was carried out. The universe was 106 patients with colon cancer diagnosis. The non-probabilistic sample was formed by the 87 patients who met, inclusion and exclusion criteria. The information was extracted from the medical records, procedure records and histologic studies. Results: the age that predominated was between 60-69 years, the female sex prevailed. The locations in the rectosigmoide were accentuated. The adenocarcinomas were the anatomical-pathological types that stood out. Conclusions: the group of ages between 60-69 years, of the female sex, predominated. The change in the habit intestinal was the clinical manifestation. The most frequent histological type of the lesion was the adenocarcinoma in more than half of the cases.

Performance of multitarget stool DNA testing in African American patients.

BACKGROUND: Multitarget stool DNA (mt-sDNA) is an approved method for colon cancer screening that is especially relevant for patients who cannot undergo colonoscopy. Although the test performance has been evaluated in a large clinical trial, it was limited to a predominantly white population. Given differences in the epidemiology and biology of colon cancer in African American individuals, the authors sought to compare the performance of mt-sDNA between racial groups. METHODS: The authors prospectively identified patients aged ≥40 years who were referred for colonoscopy at an academic medical center and 2 satellite facilities. Prior to the colonoscopy, the authors collected stool for mt-sDNA and fecal immunochemical testing (FIT). They compared the sensitivity, specificity, and receiver operating characteristic curve between African American and white patients for the detection of advanced lesions or any adenoma. RESULTS: A total of 760 patients were included, 34.9% of whom were African American. The prevalence of any adenoma (38.9% for African American patients and 33.9% for white patients) and that for advanced lesions (6.8% and 6.7%, respectively) were similar between groups. The overall sensitivities of mt-sDNA for the detection of advanced lesions and any adenoma were 43% and 19%, respectively, and the specificities were 91% and 93%, respectively. In general, mt-sDNA was more sensitive and less specific than FIT. When stratified by race, the sensitivity, specificity, and receiver operating characteristic curve area were similar between African American and white patients for both mt-sDNA and FIT. CONCLUSIONS: Test performance characteristics of mt-sDNA were comparable in African American and white patients. Given the lower uptake of colonoscopy in African American individuals, mt-sDNA may offer a promising screening alternative in this patient population.

Evaluation of Patients with an Apparent False Positive Stool DNA Test: The Role of Repeat Stool DNA Testing.

BACKGROUND: There is uncertainty as to the appropriate follow-up of patients who test positive on multimarker stool DNA (sDNA) testing and have a colonoscopy without neoplasia. AIMS: To determine the prevalence of missed colonic or occult upper gastrointestinal neoplasia in patients with an apparent false positive sDNA. METHODS: We prospectively identified 30 patients who tested positive with a commercially available sDNA followed by colonoscopy without neoplastic lesions. Patients were invited to undergo repeat sDNA at 11-29 months after the initial test followed by repeat colonoscopy and upper endoscopy. We determined the presence of neoplastic lesions on repeat evaluation stratified by results of repeat sDNA. RESULTS: Twelve patients were restudied. Seven patients had a negative second sDNA test and a normal second colonoscopy and upper endoscopy. In contrast, 5 of 12 subjects had a persistently positive second sDNA test, and 3 had positive findings, including a 3-cm sessile transverse colon adenoma with high-grade dysplasia, a 2-cm right colon sessile serrated adenoma with dysplasia, and a nonadvanced colon adenoma (p = 0.045). These corresponded to a positive predictive value of 0.60 (95% CI 0.17-1.00) and a negative predictive value of 1.00 (95% CI 1.00-1.00) for the second sDNA test. In addition, the medical records of all 30 subjects with apparent false positive testing were reviewed and no documented cases of malignant tumors were recorded. CONCLUSIONS: Repeat positive sDNA testing may identify a subset of patients with missed or occult colorectal neoplasia after negative colonoscopy for an initially positive sDNA. High-quality colonoscopy with careful attention to the right colon in patients with positive sDNA is critically important and may avoid false negative colonoscopy.

Circulating cell-free DNA as a biomarker in the diagnosis and prognosis of colorectal cancer

Abstract Colorectal cancer (CRC) is a disease without evident clinical symptoms in early stages, leading to late diagnosis and disease management. Current diagnostic and prognostic tools require invasive procedures and circulating molecular biomarkers fail to have optimal sensitivity and specificity. Circulating biomarkers with high clinical performance may be valuable for early diagnosis and prognosis of CRC. The purpose of this review was to investigate the application of circulating cell-free DNA (ccfDNA) in CRC diagnosis and prognosis and the analytical methods used in blood samples in articles published between 2005 and 2016. Based on specific inclusion and exclusion criteria, 26 articles were selected. Most studies used ccfDNA quantification as the molecular biomarker. The analytical method was mainly based on the quantitative polymerase chain reaction (qPCR). Biomarkers based on aberrantly methylated genes (n=6) and ccfDNA integrity/fragmentation (n=2) were also used for the CRC diagnosis. The CRC prognosis used the detection of oncogene mutations, such as KRAS and BRAF, in ccfDNA. Significant differences were found in variables among the studies revealing potential bias. ccfDNA quantification as a diagnostic biomarker for CRC has promising results but it lacks clinical specificity since other diseases present a similar increase in ccfDNA content. However, increasing research in the epigenomic field can lead the way to a clinically specific biomarker for the CRC early diagnosis. As for the analytical method, qPCR and derivatives seem to be a perfectly valid technique. The use of ccfDNA quantification in CRC prognosis seems promising. The attempt to use the ccfDNA quantification in clinical practice may reside in the prognosis using a qPCR technique.

Genetic Biomarker Prevalence Is Similar in Fecal Immunochemical Test Positive and Negative Colorectal Cancer Tissue.

BACKGROUND: Fecal immunochemical test (FIT) screening detects most asymptomatic colorectal cancers. Combining FIT screening with stool-based genetic biomarkers increases sensitivity for cancer, but whether DNA biomarkers (biomarkers) differ for cancers detected versus missed by FIT screening has not been evaluated in a community-based population. AIMS: To evaluate tissue biomarkers among Kaiser Permanente Northern California patients diagnosed with colorectal cancer within 2 years after FIT screening. METHODS: FIT-negative and FIT-positive colorectal cancer patients 50-77 years of age were matched on age, sex, and cancer stage. Adequate DNA was isolated from paraffin-embedded specimens in 210 FIT-negative and 211 FIT-positive patients. Quantitative allele-specific real-time target and signal amplification assays were performed for 7 K-ras mutations and 10 aberrantly methylated DNA biomarkers (NDRG4, BMP3, SFMBT2_895, SFMBT2_896, SFMBT2_897, CHST2_7890, PDGFD, VAV3, DTX1, CHST2_7889). RESULTS: One or more biomarkers were found in 414 of 421 CRCs (98.3%). Biomarker expression was not associated with FIT status, with the exception of higher SFMBT2_897 expression in FIT-negative (194 of 210; 92.4%) than in FIT-positive cancers (180 of 211; 85.3%; p = 0.02). There were no consistent differences in biomarker expression by FIT status within age, sex, stage, and cancer location subgroups. CONCLUSIONS: The biomarkers of a currently in-use multi-target stool DNA test (K-ras, NDRG4, and BMP3) and eight newly characterized methylated biomarkers were commonly expressed in tumor tissue specimens, independent of FIT result. Additional study using stool-based testing with these new biomarkers will allow assessment of sensitivity, specificity, and clinical utility.

Burden of waiting for surveillance CT colonography in patients with screen-detected 6-9 mm polyps.

PURPOSE: We assessed the burden of waiting for surveillance CT colonography (CTC) performed in patients having 6-9 mm colorectal polyps on primary screening CTC. Additionally, we compared the burden of primary and surveillance CTC. MATERIALS AND METHODS: In an invitational population-based CTC screening trial, 101 persons were diagnosed with <3 polyps 6-9 mm, for which surveillance CTC after 3 years was advised. Validated questionnaires regarding expected and perceived burden (5-point Likert scales) were completed before and after index and surveillance CTC, also including items on burden of waiting for surveillance CTC. McNemar's test was used for comparison after dichotomization. RESULTS: Seventy-eight (77 %) of 101 invitees underwent surveillance CTC, of which 66 (85 %) completed the expected and 62 (79 %) the perceived burden questionnaire. The majority of participants (73 %) reported the experience of waiting for surveillance CTC as 'never' or 'only sometimes' burdensome. There was almost no difference in expected and perceived burden between surveillance and index CTC. Waiting for the results after the procedure was significantly more burdensome for surveillance CTC than for index CTC (23 vs. 8 %; p = 0.012). CONCLUSION: Waiting for surveillance CTC after primary CTC screening caused little or no burden for surveillance participants. In general, the burden of surveillance and index CTC were comparable. KEY POINTS: • Waiting for surveillance CTC within a CRC screening caused little burden • The vast majority never or only sometimes thought about their polyp(s) • In general, the burden of index and surveillance CTC were comparable • Awaiting results was more burdensome for surveillance than for index CTC.

Computer tomography colonography participation and yield in patients under surveillance for 6-9 mm polyps in a population-based screening trial.

PURPOSE: Surveillance CT colonography (CTC) is a viable option for 6-9 mm polyps at CTC screening for colorectal cancer. We established participation and diagnostic yield of surveillance and determined overall yield of CTC screening. MATERIAL AND METHODS: In an invitational CTC screening trial 82 of 982 participants harboured 6-9 mm polyps as the largest lesion(s) for which surveillance CTC was advised. Only participants with one or more lesion(s) ≥6 mm at surveillance CTC were offered colonoscopy (OC); 13 had undergone preliminary OC. The surveillance CTC yield was defined as the number of participants with advanced neoplasia in the 82 surveillance participants, and was added to the primary screening yield. RESULTS: Sixty-five of 82 participants were eligible for surveillance CTC of which 56 (86.2 %) participated. Advanced neoplasia was diagnosed in 15/56 participants (26.8 %) and 9/13 (69.2 %) with preliminary OC. Total surveillance yield was 24/82 (29.3 %). No carcinomas were detected. Adding surveillance results to initial screening CTC yield significantly increased the advanced neoplasia yield per 100 CTC participants (6.1 to 8.6; p < 0.001) and per 100 invitees (2.1 to 2.9; p < 0.001). CONCLUSION: Surveillance CTC for 6-9 mm polyps has a substantial yield of advanced adenomas and significantly increased the CTC yield in population screening. KEY POINTS: • The participation rate in surveillance CT colonography (CTC) is 86 %. • Advanced adenoma prevalence in a 6-9 mm CTC surveillance population is high. • Surveillance CTC significantly increases the yield of population screening by CTC. • Surveillance CTC for 6-9 mm polyps is a safe strategy. • Surveillance CTC is unlikely to yield new important extracolonic findings.

HUMAN DNA QUANTIFICATION IN THE STOOLS OF PATIENTS WITH COLORECTAL CANCER

Background - Colorectal cancer is one of the main cause of cancer in the world. Colonoscopy is the best screen method, however the compliance is less than 50%. Quantification of human DNA (hDNA) in the feces may be a possible screen non-invasive method that is a consequence of the high proliferation and exfoliation of cancer cells. Objective - To quantify the human DNA in the stools of patients with colorectal cancer or polyps. Methods - Fifty patients with CRC, 26 polyps and 53 with normal colonoscopy were included. Total and human DNA were analyzed from the frozen stools. Results - An increased concentration of hDNA in the stools was observed in colorectal cancer patients compared to controls and polyps. Tumors localized in the left side of the colon had higher concentrations of hDNA. There were no difference between polyps and controls. A cut off of 0.87 ng/mL of human DNA was determined for colorectal cancer patients by the ROC curve, with a sensitivity of 66% and a specificity of 86.8%. For polyps the cut off was 0.41, the sensitivity was 41% and the specificity 77.4%. Conclusion - A higher concentration of hDNA had been found in colorectal cancer patients The quantification of hDNA from the stools can be a trial method for the diagnosis of colorectal cancer.

Contexto - O câncer colorretal é, mundialmente, uma das principais causas de câncer. A colonoscopia é o melhor método de rastreamento, no entanto a adesão é inferior a 50%. A quantificação de DNA humano (hDNA) nas fezes pode ser um possível método não invasivo de rastreamento, que é consequência da elevada proliferação e esfoliação de células cancerosas. Objetivo - Quantificar o DNA humano nas fezes de pacientes com câncer colorretal ou pólipos Métodos - Cinquenta pacientes com câncer colorretal, 26 pólipos e 53 com colonoscopia normal foram incluídas. DNA total e humano foram analisados a partir de fezes congeladas. Resultados - Maior concentração de hDNA nas fezes foi observada em pacientes com câncer colorretal em comparação com controles e pólipos. Pacientes com tumores localizados no cólon esquerdo apresentaram concentrações mais elevadas de hDNA. Não houve diferença entre pólipos e controles. Um nível de corte de 0.87ng/mL de DNA humano foi determinado para pacientes com câncer colorretal pela curva ROC, com sensibilidade de 66% e especificidade de 86,8%. Para pólipos o nível de corte foi de 0,41, a sensibilidade foi de 41% e a especificidade de 77,4%. Conclusão - Maior concentração de hDNA foi encontrada em pacientes com câncer colorretal. A quantificação de hDNA das fezes pode ser um método de rastreio do câncer colorretal.

Participation in four rounds of a French colorectal cancer screening programme with guaiac faecal occult blood test: a population-based open cohort study.

OBJECTIVES: Four randomized controlled trials have demonstrated the efficacy of screening using a guaiac faecal occult blood test (gFOBT) on colorectal cancer (CRC) mortality. Whether their results are transposable to the real world is unknown. This study aimed to assess the determinants of participation in the first four rounds of the CRC screening programme using a gFOBT implemented since 2003 in the Haut-Rhin (Alsace) part of the French national programme. METHODS: We performed a population-based open cohort study of all residents aged 50-74, around 200,000 people. They were invited by mail to participate every other year. The gFOBT kits (Hemoccult II) were first provided by general practitioners, and then directly mailed to persons who failed to comply. RESULTS: The uptake decreased significantly across all rounds, from 54.3% to 47.1% (p < 0.0001), mainly in people younger than 60. The proportion of people screened by general practitioners increased significantly from 77.0% in the first round to 84.2% in the fourth (p < 0.01). Overall, 61.3% of the invited population participated at least once, and 14.3% had completed all the four tests. The colonoscopy uptake was around 91%, among the highest ever reported. CONCLUSIONS: Despite the involvement of general practitioners, the uptake and adherence to repeat testing are modest and deteriorate with time, so that the reduction in CRC mortality in reality will be significantly lower than that in the trials. The benefit-risk balance of the French programme is, at present, less favourable than that shown in the trials.

Two-week wait symptoms are prevalent in screened patients with a positive faecal occult blood test but do not predict cancer.

AIM: Lower gastrointestinal (LGI) symptoms are prevalent in patients screened for bowel cancer yet do not predict a finding of cancer. This study evaluates symptoms in patients with these characteristics against the 2-week wait (2ww) criteria to determine whether they predicted cancer in these patients. METHOD: A prospective cohort study was performed. Patients with a positive faecal occult blood (FOB) test attending our unit over a 7-month period were included. Data on symptom prevalence, frequency and duration were collected and assessed against the 2ww criteria. Associations between symptom prevalence and patient outcome were investigated using the χ(2) test. RESULTS: Three hundred and ninety-seven patients were included and 37 (9%) were found to have colorectal cancer (CRC). The prevalence of undefined LGI symptoms was 71% and appeared comparable between those with and without CRC (65 vs 72%, P = 0.385). 2ww symptoms were reported in 147 (37%), with 2ww change in bowel habit in 10% and 2ww rectal bleeding in 31%. 2ww symptom prevalence was similar in those with and without cancer (38 vs 37%, P = 0.915). No significant differences in overall 2ww prevalence or prevalence of individual 2ww symptoms were demonstrated between those with a normal colonoscopy or one showing cancer, polyps or other pathology. Twenty nine per cent of patients with 2ww symptoms had reported these to their GP. CONCLUSION: Undefined LGI symptoms are prevalent in FOB-positive patients but do not predict CRC. 2ww symptoms are also highly prevalent, yet similarly fail to predict cancer. Further efforts to increase public awareness of cancer symptoms are required, whilst false reassurance from a negative FOB result should be discouraged.

Estudo sobre a acurácia da colonoscopia na detecção do câncer colorretal / A study on the accuracy of colonoscopy in detecting colorectal cancer

Justificativa e objetivos: o câncer colorretal (CCR) é a terceira neoplasia maligna mais comum e a segunda maior causa de morte relacionada ao câncer. A colonoscopia é a técnica de mais acuidade para o diagnóstico de lesões estruturais do cólon. O objetivo deste estudo foi calcular o índice de concordância diagnóstica (Kappa) da colonoscopia na suspeição de câncer colorretal comparando com o exame histopatológico(padrão-ouro) em pacientes sintomáticos examinados entre 2007 e 2010.Pacientes e métodos: foram estudados 233 casos de forma observacional e prospectiva. Resultados: alterações colonoscópicas suspeitas de câncer colorretal estavam presentes em 24 (6,87%) dos pacientes submetidos à colonoscopia e o diagnóstico foi confirmado pela histopatologia em 21 casos. Os locais mais acometidos pelo CCR foram o cólon (62,5%) e o reto (37,5%), não sendo encontradas lesões em ânus e canal anal. O cólon esquerdo foi o mais acometido (75%), com 58,33% das lesões em região sigmoide; e no cólon direito foram encontrados 25% das lesões. Conclusão: o índice Kappa de concordância diagnóstica nesta amostra na detecção do câncer colorretal foi de 0,88 com IC 0,78 e 0,98, considerado substancial.

Justification and objective: colorectal cancer (CRC) is the third most common malignant neoplasm and the second major cause of cancer-related death. Colonoscopy is the most accurate technique for diagnosing structural lesions in the colon. The aim of this study was to calculate the diagnostic agreement rate (Kappa) of colonoscopy in cases of suspected colorectal cancer and histopathological examination (gold standard) in symptomatic patients examined between 2007-2010. Patients and methods: 233 cases were assessed in this observational prospective study. Results: changes upon colonoscopy suggestive of colorectal cancer were present in 24 (6.87%) patients submitted to colonoscopyand diagnosis was confirmed by histopathology in 21 cases. Most affected by CRC were the colon (62.5%) and rectum (37.5%), and no lesions were found in the anus or anal canal. The left colon was the most affected (75%), with 58.33% of the lesions in the sigmoid region; and 25% of lesions were found in the right colon. Conclusion: The Kappa index of diagnostic agreement for this sample in the detection of colorectal cancer was 0.88 with CI 0.78 and 0.98, considered substantial.

Aspectos genéticos do câncer colorretal e seu impacto no manejo da doença / Genetic aspects of colorectal cancer and its impact on disease management

Diversos estudos buscam agregar métodos de diagnóstico e de terapêutica com o intuito de diminuir a incidência e a morbimortalidade do câncer colorretal (CCR). Novas tecnologias propostas para esse fim decorrem da análise do DNA fecal, terapias voltadas para alvos moleculares específicos e determinação de resposta terapêutica e prognóstico com a análise genética. Este estudo procura revisar essas novas conquistas e apresentá-las para que possam ser usadas de forma prática e objetiva.

Several studies seek to enhance diagnosis and treatment of colorectal cancer (CRC) in order to reduce its incidence and mortality. New technologies proposed include the analysis of fecal DNA, therapies aimed at specific molecular targets and determination of therapeutic response and prognosis with genetic analysis. This study aims to review these new achievements and present them so that they can be used in a practical and objective way.

Diagnostic value of occult fecal blood testing for colorectal cancer screening.

AIM: To evaluate the diagnostic value of occult fecal blood testing in mass colorectal cancer screening. METHODS: A reverse passive hemagglutination reaction fecal occult blood test (RPHA-FOBT) and colorectal cancer risk factor quantitative method were used as preliminary screening for colorectal cancer. A 60-cm fiber optic colonoscopy was used to validate the preliminary screen and was used to detect colorectal cancer in a community of 75813 subjects. RESULTS: Compared to the 60-cm fiber optic colonoscopy as a standard reference, FOBT has a sensitivity of 41.9%, specificity of 95.8%, Youden's index of 0.38, and positive predictive value of 0.68%. These results increased with subject age from the first detection. A 3-year follow up in the target mass showed that all new cases had initially been FOBT-negative. CONCLUSION: The value of FOBT as an indicator of colorectal cancer in mass screening is limited.